Evidence map›Paper›PMID 31337728›Full record

ArticlemBio2019

Durable Long-Term Bacterial Engraftment following Encapsulated Fecal Microbiota Transplantation To Treat Clostridium difficile Infection.

Christopher Staley, Thomas Kaiser, Byron P Vaughn, Carolyn Graiziger, Matthew J Hamilton, Amanda J Kabage, Alexander Khoruts, Michael J Sadowsky

3 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in mBio, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04300426 phase2completednot on this mapstarted 2020, after this paper: background citation

Aiming to Reduce Disease-related Gastrointestinal Symptoms in Systemic Sclerosis by Repeat Intestinal Infusions of Anaerobic Cultivated Human Intestinal Microbiome (ACHIM); a Randomized, Double-blind Placebo-controlled 20 Week Study

TypeinterventionalSponsorOslo University HospitalRan2020 to 2022Enrolled75ConditionsSystemic SclerosisArms"ACHIM" as solute (10^9 intestinal microbes/ml)
NCT07490054 phase1recruitingnot on this mapstarted 2025, after this paper: background citation

An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of Intestinal Microbiota Transplantation In Patients With Chronic Heart Failure

TypeinterventionalSponsorMelana Yuzefpolskaya, MDRan2025 to 2027Enrolled40ConditionsChronic Heart FailureArmsMTP-101-C encapsulated Microbiota, Vancomycin, Neomycin
NCT07756255 phase2not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Feasibility, Safety and Tolerability of Fecal Microbiota Transplantation in an Adolescent Population With Attention Deficit Hyperactivity Disorder (ADHD)

TypeinterventionalSponsorUniversity of CalgaryRan2026 to 2029Enrolled64ConditionsADHD, ADHD - Attention Deficit Disorder With Hyperactivity, ADHD - Combined TypeArmsFecal Microbiota Transplant (FMT), Nitazoxanide 500mg BID, Vancomycin 250mg BID, Placebo Vancomycin, Placebo Nitazoxanide
3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 81 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Randomized Double-Blind Phase II Trial of Fecal Microbiota Transplantation Versus Placebo in Allogeneic Hematopoietic Cell Transplantation and AML.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Trial
  7. Trial
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Avoiding Premature Antibiotic Use in RecurrentACG case reports journal · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Current perspectives on fecal microbiota transplantation in inflammatory bowel disease.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Christopher StaleyDivision of Basic & Translational Research, Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
Thomas KaiserDivision of Basic & Translational Research, Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
Byron P VaughnDivision of Gastroenterology, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Carolyn GraizigerDivision of Gastroenterology, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Matthew J HamiltonBioTechnology Institute, University of Minnesota, Saint Paul, Minnesota, USA.
Amanda J KabageDivision of Gastroenterology, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
Alexander Khoruts *BioTechnology Institute, University of Minnesota, Saint Paul, Minnesota, USA.
Michael J Sadowsky *BioTechnology Institute, University of Minnesota, Saint Paul, Minnesota, USA sadowsky@umn.edu.ORCID 0000-0001-8779-2781
University of Minnesota · US

Funding

The role of bile acid metabolism recovery in treatment of C. difficile infectionR21AI114722 · NIAID · UNIVERSITY OF MINNESOTA · PI CHEN, CHI, KHORUTS, ALEXANDER · 2015 to 2016
$414k
NIAID NIH HHS R21 AI114722
6 · The paper itself

Abstract

Fecal microbiota transplantation (FMT) has become a common rescue therapy for recurrent

Indexed as

Fecal Microbiota TransplantationAdultAgedBacteroidetesBayes TheoremClostridioides difficileClostridium InfectionsCohort StudiesFecesFemaleFreezingHigh-Throughput Nucleotide SequencingHumansMaleMetforminMicrobiotaMetforminRNA, Ribosomal, 16SBacteroidescapsule FMTdonorengraftmentfecal transplantstable

Identifiers

PMID31337728
PMCPMC6650559
OpenAlexW2963424654

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.